How many times can I stop taking Gosatuzumab (Todavi)? What are the criteria and conditions for discontinuing medication?

Gosatuzumab (Trodelvy) is an antibody-drug conjugate (ADC), mainly used to treat triple-negative breast cancer (TNBC) and other advanced or metastatic tumors. Gosatuzumab works by targeting and inhibiting the Trop-2 receptor on cancer cells, releasing the drug to kill cancer cells. In clinical applications, how to determine whether a patient can discontinue medication usually requires a series of standards and conditions.

The decision to continue treatment with gosatuzumab is usually based on efficacy and tolerability. For most patients, treatment is usually continued until disease progression or intolerable side effects occur before discontinuation is considered. If the patient achieves significant results during treatment, such as significant tumor shrinkage or stabilization, and no serious side effects occur, discontinuation of the drug may be considered. Based on clinical trial results, the standard of treatment is usually one injection every two weeks, with patients receiving a series of treatments followed by imaging studies such as CT or MRI to assess the effectiveness of the treatment.

The main conditions for discontinuation include:

1. Disease progression: If the tumor progresses or recurs significantly during treatment, it means that the drug is no longer effective. At this time, it is necessary to consider stopping the drug and switching to other treatment options.

2.Intolerable side effects: Although gosatuzumab is clinically well tolerated, a small number of patients may experience serious side effects, such as severe gastrointestinal reactions, leukopenia, etc. If these side effects seriously affect your quality of life or threaten your life, your doctor may recommend stopping the medication.

3.Clinical judgment: Depending on individual differences among patients, doctors may also decide whether to discontinue medication based on treatment response, quality of life, and the patient's overall health.

Even after stopping the drug, patients still need regular follow-up and monitoring to assess whether the tumor has recurred or progressed. Monitoring after discontinuation usually includes imaging studies and blood tests. For some patients, although the tumor does not progress immediately after stopping the drug, it is still necessary to maintain a high level of vigilance and conduct regular examinations to ensure that the disease is in a stable state.

Discontinuation of gosatuzumab is usually based on efficacy, tolerability, and disease progression. Criteria for discontinuation include disease progression or side effects that are intolerable to the patient. Monitoring and individualized medical evaluation during treatment are key to ensuring treatment effectiveness and patient safety.

Reference materials:https://www.trodelvy.com/